# Immunogenicity of Novel Oral Poliovirus Vaccine Type 2 (nOPV2), bOPV and IPV

> **NCT06114810** · PHASE4 · UNKNOWN · sponsor: **International Centre for Diarrhoeal Disease Research, Bangladesh** · enrollment: 880 (estimated)

## Conditions studied

- Polio

## Interventions

- **BIOLOGICAL:** polio vaccines: nOPV2, bOPV, IPV

## Key facts

- **NCT ID:** NCT06114810
- **Lead sponsor:** International Centre for Diarrhoeal Disease Research, Bangladesh
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-11
- **Primary completion:** 2024-06
- **Final completion:** 2024-09
- **Target enrollment:** 880 (ESTIMATED)
- **Last updated:** 2023-11-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06114810

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06114810, "Immunogenicity of Novel Oral Poliovirus Vaccine Type 2 (nOPV2), bOPV and IPV". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06114810. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*